Clinical Trial Update: A Study of an Infectivity Enhanced Suicide Gene Expressing Adenovirus for Ovarian Cancer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating an infectivity-enhanced suicide gene expressing adenovirus for ovarian cancer and other gynecologic cancers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Infectivity-enhanced suicide gene expressing adenovirus (suicide gene expressing adenovirus vector)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Ovarian Cancer | Phase 1 | Status: COMPLETED